{"DataElement":{"publicId":"3297381","version":"1","preferredName":"Kaposi Sarcoma Overall Response Category","preferredDefinition":"Text term to represent the best overall response to treatment for a patient with Kaposi's Sarcoma (KS)","longName":"KS_OVLL_RESP_CAT","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3297376","version":"1","preferredName":"Kaposi Sarcoma Overall Response","preferredDefinition":"information relating to the response of a patient's Kaposi Sarcoma (a malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells) to treatment with an agent._Response; a bodily process occurring due to the effect of some foregoing stimulus or agent._Including everything.","longName":"KS_OVLL_RESP","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2639367","version":"1","preferredName":"Kaposi Sarcoma","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","longName":"C9087","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"30BF3151-5EE1-1E4A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-05-18","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-05-18","modifiedBy":"ONEDATA","dateModified":"2007-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2982872","version":"1","preferredName":"Overall Response","preferredDefinition":"Including everything.:Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.","longName":"C25605:C25755","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Overall","conceptCode":"C25605","definition":"Including everything.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C9811FE-FA15-354D-E040-BB89AD437338","latestVersionIndicator":"Yes","beginDate":"2010-01-07","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-01-07","modifiedBy":"ONEDATA","dateModified":"2010-01-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B00D3CFD-BF8A-0B96-E040-BB89AD4336CD","latestVersionIndicator":"Yes","beginDate":"2011-10-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3297380","version":"1","preferredName":"Kaposi Sarcoma Response Category","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS)._Response; a bodily process occurring due to the effect of some foregoing stimulus or agent._Category; used informally to mean a class of things.","longName":"KS_RESP_CAT","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"30","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Partial response","valueDescription":"Partial Response","ValueMeaning":{"publicId":"2559721","version":"1","preferredName":"Partial Response","longName":"2559721","preferredDefinition":"A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Response","conceptCode":"C18212","definition":"A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B656-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SOKKERL","dateModified":"2023-09-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B00D425B-D7B7-D722-E040-BB89AD431965","beginDate":"2004-01-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-24","modifiedBy":"ONEDATA","dateModified":"2011-10-24","deletedIndicator":"No"},{"value":"Stable disease","valueDescription":"Stable Disease","ValueMeaning":{"publicId":"2560100","version":"1","preferredName":"Stable Disease","longName":"2560100","preferredDefinition":"Cancer that is neither decreasing nor increasing in extent or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Disease","conceptCode":"C18213","definition":"A disease that is neither decreasing nor increasing in extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B7D1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"KUMMEROA","dateModified":"2022-09-13","changeDescription":"Manually curated for OHSU 10262","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B00D425B-D7CB-D722-E040-BB89AD431965","beginDate":"2004-01-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-24","modifiedBy":"ONEDATA","dateModified":"2011-10-24","deletedIndicator":"No"},{"value":"Complete response","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"2577915","version":"1","preferredName":"Complete Remission","longName":"2577915","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD68-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB0F5528-E247-CEB4-E040-BB89AD434776","beginDate":"2004-01-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-12","modifiedBy":"ONEDATA","dateModified":"2012-03-12","deletedIndicator":"No"},{"value":"Progressive disease","valueDescription":"PD","ValueMeaning":{"publicId":"3090977","version":"1","preferredName":"PD","longName":"3090977","preferredDefinition":"A disease process that is increasing in scope or severity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progressive Disease","conceptCode":"C35571","definition":"A clinical, pathologic, and/or molecular finding indicating that the course of a disease is worsening in terms of extent or severity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"871570E4-2924-7B29-E040-BB89AD43510F","latestVersionIndicator":"Yes","beginDate":"2010-05-21","endDate":null,"createdBy":"ALAIS","dateCreated":"2010-05-21","modifiedBy":"COOPERM","dateModified":"2019-03-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB0F5528-E251-CEB4-E040-BB89AD434776","beginDate":"2004-01-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-12","modifiedBy":"ONEDATA","dateModified":"2012-03-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3297379","version":"1","preferredName":"Kaposi Sarcoma Response Category","preferredDefinition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).:Response; a bodily process occurring due to the effect of some foregoing stimulus or agent.:Category; used informally to mean a class of things.","longName":"C9087:C25755:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Response","conceptCode":"C25755","definition":"Any act or phenomena, or behavior, constituting a reply or reaction of a living organism or its part to some foregoing stimulus or agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B00D425B-D788-D722-E040-BB89AD431965","latestVersionIndicator":"Yes","beginDate":"2011-10-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-24","modifiedBy":"ONEDATA","dateModified":"2011-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B00D425B-D799-D722-E040-BB89AD431965","latestVersionIndicator":"Yes","beginDate":"2011-10-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-24","modifiedBy":"REEVESD","dateModified":"2012-03-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[{"name":"AMC","type":"USED_BY","context":"AMC"},{"name":"RSORRES","type":"OID, AMC","context":"AMC"}],"ReferenceDocuments":[{"name":"KS Overall Response","type":"Preferred Question Text","description":"KS Overall Response","url":null,"context":"NCIP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Response","url":null,"context":"AMC"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B00D425B-D7D5-D722-E040-BB89AD431965","latestVersionIndicator":"Yes","beginDate":"2011-10-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-10-24","modifiedBy":"ALAIS","dateModified":"2020-07-24","changeDescription":"Curated to support NCI CCR clinical trial","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}